Thus, although SM16 administration resulted in significantly inhibited tumor growth (Fig. 5) and concomitant increase in the CD4+CD25−FoxP3+ Treg-like subpopulation (Fig. 6a), it did not significantly increase the CD4+CD25+FoxP3+ Treg subpopulation in the spleen, lymph nodes or tumor microenvironment of TBM (Fig. 6b). This evidence concerns the gene CD4 and neoplasm.